Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded FDA OTC inspection authority will ease global marketing -- FDAer.

This article was originally published in The Tan Sheet

Executive Summary

LABEL PRINTING ERROR REDUCTION THROUGH GMPs should be priority for FDA and OTC drug manufacturers, FDA New Jersey District Director Douglas Ellsworth recommended at the Nonprescription Drug Manufacturers Association's annual small business seminar in East Rutherford, N.J. March 11-12. Noting that FDA has worked with industry for "a number of years" to reduce the amount of recalls related to mislabeling problems, such as the wrong label being attached to bottles, the FDAer said "we need to focus some of our efforts on the printing aspect -- what controls are necessary" to avoid misprints.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel